3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Breast
1
Conditions
Breast Neoplasms
9
Neoplasms by Site
1
Neoplasms
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Breast Diseases
1
Brain Neoplasms
1
Brain Diseases
1
Advanced Breast Cancer
1
Interventions
Paclitaxel
26
pembrolizumab
24
Docetaxel
20
Capecitabine
19
Fulvestrant
17
Trastuzumab
16
Anastrozole
15
Cyclophosphamide
14
Lapatinib
13
Letrozole
11
Carboplatin
11
Radiotherapy
10
Doxorubicin
10
palbociclib
9
Therapeutics
9
Nivolumab
9
Exercise
9
Gemcitabine
8
Cisplatin
8
Blood Specimen Collection
8
Tamoxifen
7
Bevacizumab
7
liposomal doxorubicin
6
exemestane
6
abemaciclib
6
Vinorelbine
6
Standard of Care
6
Fluorouracil
6
atezolizumab
5
Surveys and Questionnaires
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
RAD1901
×
Breast
×
Clear all
NCT05386108
2026-06-04
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2
Recruiting
73 enrolled